On Tuesday, small cap watchmaker Movado Group, Inc (NYSE: MOV) surged 10.5% after it reported earnings and it�� the only real pure play watchmaker as�mid cap Fossil Group Inc (NASDAQ: FOSL) has diversified into other accessories and has almost tripled over the past five years. Given the problems many clothing retailers are having, its probably worth taking a closer look whether or not watchmakers or other accessory stocks might make better investments.
What�You Need to Know About Movado Group and Fossil GroupHere is what you need to know about�both watchmakers:
Small cap Movado Group, Inc. designs, manufactures and distributes watches from ten of the most ��ecognized and respected��names in watchmaking: Movado, Concord, EBEL,�ESQ Movado, Coach, HUGO BOSS, Juicy Couture, Lacoste, Tommy Hilfiger and Scuderia Ferrari. The Movado Group has�manufacturing facilities in Switzerland; its corporate headquarters in Paramus, New Jersey, USA and Bienne, Switzerland; and�sales and distribution offices around the world as its�timepieces are sold throughout North and South America, Europe, Asia and the Far East. Yesterday, Movado Group reported a 17% revenue increase to $138.3 million�thanks to higher�sales of its namesake watches and Scuderia Ferrari plus the later timing of the Swiss international watch and jewelry fair held annually in Basel. Net income�came in at�$20.7 million verses $14.7 million. The Movado Group also raised its full-year earnings and revenue forecasts plus raised quarterly dividend by 60% to 8 cents per share.�It should be noted that in the earnings call, the COO stated:��he sales growth is all driven by productivity. When you look at it -- and I'll remind you of the percentages of market growth that took place in the U.S. When you look at the Movado brand -- and again, this is third-party independent data -- the market excluding Movado in our price points of $300 to $3,000, grew 1% for the 12-month period ended June 30, 2013. Movado grew in excess of 15%.
Top Consumer Stocks To Invest In 2015: Skullcandy Inc (SKUL)
Skullcandy, Inc., incorporated on May 20, 2005, is a designer, marketer and distributor of performance audio and gaming headphones and other accessory related products under the Skullcandy, Astro Gaming and 2XL by Skullcandy brands. The Company's products are sold and distributed through a variety of channels in the United States and approximately 80 countries worldwide. The Company is engaged in the distribution of headphones in specialty retailers focused on action sports and the youth lifestyle, such as Zumiez, Tilly�� and hundreds of independent snow, skate and surf retailers. It distributes through consumer electronics, mass, sporting goods and mobile phone retailers, such as Best Buy, Target, Dick�� Sporting Goods and AT&T Wireless. Skullcandy products are also sold through its Website.
The Company�� product line include dB Collecti; Mobility Collectio, which targets mobile channel with product features designed to work on cell phones and smartphones, such as the Apple iPhone, and 2XL, which represents traditional sports, motor sports and hip-hop and rock and roll music. The Company sponsors athletes, disc jockeys (DJs), musicians, artists and events within all areas of action sports and the indie and hip-hop music genres. Through its Websites, skullcandy.com, skullcandy.tv, ca.skullcandy.com, eu.skullcandy.com, uk.skullcandy.com, 2xl.com, astrogaming.com, astrogaming.co.uk and astrogaming.fr listen to music by its sponsored artists, read blog updates on events, athletes, DJs, musicians and artists, and shop for Skullcandy and Astro Gaming products.
The Company competes with Sony, JVC, Bose, Beats by Dr. Dre, Nixon, adidas, Incase, Urbanears, Monster Cable Products, Sol Republic, iFrogz,Nike and Sennheiser.
Advisors' Opinion:- [By WWW.DAILYFINANCE.COM]
Getty Images From a door-to-door selling icon stocking up on blush after a disappointing quarter to several hotel chains checking in with strong occupancy trends, here's a rundown of the week's smartest moves and biggest blunders in the business world. Hotels -- Winners Hoteliers were apparently hopping during the first quarter. Despite the iffy weather and the equally iffy economy, the leading chains reporting this week posted surprisingly robust activity. Revenue per available room is a key metric because it tracks occupancy levels as well as prevailing overnight rates. The industry's doing well when RevPAR is positive, and that's just what we saw with this week's reports. Choice Hotels (CHH), Marriott (MAR), and Hyatt (H) clocked in with RevPAR increases of 5.6 percent, 6.3 percent and 6.5 percent, respectively. Twitter (TWTR) -- Loser Shares of Twitter hit an all-time low this week after the company posted disappointing user growth. Sure, the "all-time low" remark needs to be accompanied by the caveat that Twitter has only been trading publicly for less than six months. It's still a grim milestone for last year's most anticipated debutante. Twitter's revenue growth was fine, propelled by the recent success of its monetization initiatives. Its outlook was upbeat. However, the one thing that haunted investors this week was that Twitter had just 14 million more unique monthly visitors than it had a quarter earlier. That kind of sequential uptick would've impressed at most companies, but Twitter trades at a juicy premium to the market. #Letdown. J.C. Penney (JCP) -- Winner The struggling department store operator isn't out of the woods just yet, but at least one supplier is offering up encouraging insight. PVH (PVH) was presenting at an investor conference in Miami earlier in the week when its CEO offered up an encouraging perspective. "The Penney's business is running on or ahead of plan and given what their sales trends are," said CEO Manny Chirico,
Top Mid Cap Stocks To Watch For 2014: DiaMedica Inc (DMA)
DiaMedica Inc. (DiaMedica) is a development-stage company. The Company is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of diabetes and related diseases. DiaMedica's compound, DM-199, is a recombinant human protein for the treatment of both Type I and Type II diabetes and their complications. DiaMedica is starting a Phase I/II clinical trial for DM-199. DM-199 is a recombinant human protein, which improves glucose control, protects beta cells through the expansion of a population of antigen-specific immunosuppressive cells (Tregs), and proliferates insulin producing beta cells through the activation of certain growth factors. The Company�� DM-204 is a G-protein-coupled receptor agonist (GPCR) monoclonal antibody to treat Type II diabetes and some of the associated complication's. activating a receptor resulted in insulin sensitivity, insulin secretion and vasodilation. Advisors' Opinion:- [By Richard Rhodes]
Given this economic backdrop, and developing pressure on corporate revenues, margins, and earnings, we feel that risk is being misplaced at current levels.
The 14-day and 40-day models are now overbought. Now, the 14-day and 40-day are peaking, which would certainly indicate a correction stands as the highest probability.
The % of stocks above their 10-day moving average (dma) is at the 70%-level; still a major divergence with prices.
The % of stocks above their 200-dma stands at 77%. The 87% level marked previous highs. The 50-dma/150-dma cross breakdown now confirms a larger correction. Bottoms form between 30%-40%.
Overall, the risk-reward remains skewed to the downside, regardless of whether prices remain above trendline resistance, as our model group suggests a correction to the 110-day moving average, currently at S&P 1711.
A clear breakdown at that level would accelerate the decline towards the wide 200-dma and 380-dma range, between 1657-1571.
Top Mid Cap Stocks To Watch For 2014: Quest Diagnostics Inc (DGX)
Quest Diagnostics Incorporated (Quest Diagnostics), incorporated in 1990, is a provider of diagnostic testing, information and services, providing insights that enable patients and physicians to make healthcare decisions. Quest Diagnostics offers United States patients and physicians the access to diagnostic testing services through its nationwide network of laboratories and Company-owned patient service centers. The Company provides interpretive consultation through the medical and scientific staff. The Company is a provider of clinical testing, including gene-based and esoteric testing and anatomic pathology services, and the provider of risk assessment services for the life insurance industry. The Company also is a provider of testing for clinical trials and testing for drugs of abuse. Its diagnostics products business manufactures and markets diagnostic test kits and specialized point-of-care testing. On April 4, 2011, the Company acquired Athena Diagnostics (Athena). On May 17, 2011, the Company acquired Celera Corporation (Celera). In January 2012, the Company acquired S.E.D. Medical Laboratories. In December 2012, the Company sold all of the assets of OralDNA Labs salivary-diagnostics business to Access Genetics. Quest Diagnostics Incorporated (Quest Diagnostics) is a provider of diagnostic testing, information and services, providing insights that enable patients and physicians to make healthcare decisions. Quest Diagnostics offers United States patients and physicians the access to diagnostic testing services through its nationwide network of laboratories and Company-owned patient service centers. The Company provides interpretive consultation through the medical and scientific staff. The Company is a provider of clinical testing and the provider of risk assessment services for the life insurance industry. The Company also is a provider of testing for clinical trials and testing for drugs of abuse. In January 2012, it acquired S.E.D. Medical Laboratories. In December 2012, it sold all of the ! assets of OralDNA Labs salivary-diagnostics business to Access Genetics. In January 2013, the Company acquired the Worcester -based clinical outreach laboratory business of UMass Memorial Medical Center.
Clinical Testing
The Company is a commercial clinical testing company. Physicians use clinical tests to assist in the detection, diagnosis, evaluation, monitoring and treatment of diseases and other medical conditions. Clinical testing is generally categorized as clinical laboratory testing and anatomic pathology services. The Company offers customers the access to the test menu of clinical laboratory and anatomic pathology tests in the United States. Clinical laboratory testing generally is performed on whole blood, serum, plasma and other body fluids, such as urine, and specimens such as microbiology samples.
The Company is a provider of routine clinical testing, including testing for drugs of abuse. The Company performs routine testing through its network of laboratories and rapid response laboratories. The Company also performs routine testing at hospital laboratories that the Company manages. The Company operates laboratories round the clock. The majority of test results are delivered electronically. Routine tests measure various bodily health parameters, such as the functions of the kidney, heart, liver, thyroid and other organs. Commonly ordered tests include blood chemistries, including cholesterol levels; complete blood cell counts; urinalysis; pregnancy and other prenatal tests, and routine microbiology testing.
The Company is a provider of anatomic pathology services in the United States, through its AmeriPath, Dermpath Diagnostics and Quest Diagnostics brands. Anatomic pathology involves the diagnosis of cancer and other diseases and medical conditions through examination of tissue and cell samples taken from patients. The Company provides inpatient anatomic pathology and medical director services at hospitals throughout the country, and through ! its labor! atories. The Company provides a range of services to all anatomic pathology subspecialties. The Company provides integrated, reports that include both anatomic pathology and clinical pathology tests, enabling its pathologists to offer patients and physicians a complete analysis. The Company introduced the Leumeta family of tests for leukemia and lymphoma.
The Company is a provider in the United States of gene-based and esoteric testing. Esoteric tests include procedures in the areas of molecular diagnostics, protein chemistry, cellular immunology and advanced microbiology. Commonly ordered esoteric tests include viral and bacterial detection tests, drug therapy monitoring tests, genetic tests, autoimmune panels and complex cancer evaluations. During the year ended December 31, 2011, it acquired Athena Diagnostics, a provider of neurology testing. Its esoteric laboratories provide reference testing services to physicians, academic medical centers, hospitals and other commercial laboratories. The Company also offers gene-based tests for the predisposition, diagnosis, treatment and monitoring of cancers. The Company develops tests at its laboratories, such as Quest Diagnostics Nichols Institute. It also develops techniques and services in anatomic pathology.
In 2011, the Company introduced its melanoma treatment selection mutation panel, which is designed to assist in the personalized selection of patient therapies. The Company introduced its thyroid cancer mutation panel, which assists in the diagnosis of thyroid cancer and aids physicians and surgeons as they plan surgery and other therapies to treat and attempt to cure thyroid cancer. During 2011, it enhanced its SureSwab Vaginosis/Vaginitis Plus test. The Company introduced Accutype IL28b, a test designed to aid in the prediction of patient response to peginterferon alpha-based therapy for treating hepatitis C virus infection. In 2011, it introduced testing for very long chain fatty acids, to assist in diagnosis and monitori! ng of inh! erited disorders of fatty acid metabolism. It also introduced high resolution chromosomal analysis testing with oligonucleotide microarrays to enhance its testing services in the pre-natal and post-natal genetics areas. During 2011, the Company released a test for therapeutic drug monitoring of dabigatran, an oral anti-coagulant. The Company also released genetic testing for SLC01B1, which helps identify patients at risk for myopathy from Simvastatin therapy for cholesterol reduction. Through Athena Diagnostics, it launched several molecular genetic tests for stroke, neuromuscular diseases and mitochondrial disorders.
Healthcare Information Technology
The Company provides interoperable technologies that help healthcare organizations and physicians enter, share and access clinical information without costly information technology (IT) implementation or workflow disruption, including through its Care360 suite of products and its ChartMaxx electronic document management system for hospitals. These solutions offer access to a national healthcare provider network, including approximately 200,000 networked physicians and clinicians using Quest Diagnostics��Care360 connectivity products. The Care360 products, including its Care360 Labs and Meds, enable physicians electronically to order diagnostic tests and review test results from Quest Diagnostics and electronically to prescribe medication. As of December 31, 2011, prescriptions were written through Care360 ePrescribing at an annualized rate of 32 million medications. Using its Care360 connectivity products, physicians can securely provide diagnostic and other data to a patient�� account. It offers Gazelle, a secure mobile health platform that allows users to receive their Quest Diagnostics laboratory results, manage their personal health information, find a Quest Diagnostics location and schedule appointments directly from their smartphone.
Clinical Trials Testing
The Company is a provider of central l! aboratory! testing performed in connection with clinical research trials on new drugs, vaccines and certain medical devices. It has clinical trials testing centers in the United States and the United Kingdom, and it provides clinical trials testing in Argentina, Australia, Brazil, the People�� Republic of China and Singapore through affiliated laboratories. The Company has biomarker capabilities. In 2011, it acquired Celera, enhancing its ability to provide biomarker discovery and develop IVD test kits.
Life Insurer Services
The Company is a provider of risk assessment services to the life insurance industry in North America. It also provides risk assessment services for insurance companies doing business in many countries outside the United States. Its risk assessment services comprise underwriting support services to the life insurance industry, including laboratory testing, electronic data collection, specimen collection and paramedical examinations, medical record retrieval, case management, motor vehicle reports, telephone inspections, prescription histories and credit checks. The laboratory tests that it performs and data it gathers are designed to assist insurance companies to objectively evaluate the mortality risks of policy applicants. The majority of the testing is performed on specimens of life insurance applicants, but also includes specimens of applicants for other types of insurance. Most of its specimen collections and paramedical examinations are performed by its network of approximately 5,000 contracted paramedical examiners at the applicant�� home or workplace. The Company also offers paramedical examinations through approximately 500 of its patient service centers, and operate approximately 80 locations other than patient service centers in the United States and Canada where the Company provides paramedical examinations, bringing to approximately 580 the total number of sites where it can provide these examinations. The Company also contracts with third parties at over! an addit! ional 200 locations globally to coordinate providing these exams.
Employer Services
The Company is a provider of testing to employers for the detection of employee use of drugs of abuse. Its Quest Diagnostics Drug Testing Index, which is an annual report of its aggregate drug testing results, is used by employers, the federal government and the media to help identify and quantify drug abuse among the nation�� workforce. It provides a range of solutions for drugs of abuse, including urine, hair, blood and oral fluid tests. In 2011, it introduced Oral-Eze, its own oral fluid collection system that simplifies the collection of oral samples for routine drug testing. The Oral-Eze Oral Fluid Collector provides all the advantages of previous collection systems, with the added benefit of its indicator window technology. The Company provides wellness testing and analytic services to employers.
Diagnostic Products
Diagnostic Products include point-of-care, or near-patient and testing. The Company develops and manufactures products that enable healthcare professionals to make healthcare diagnoses, including products for point-of-care, or near-patient, testing for the professional market. The Company has several companies, including Focus Diagnostics, HemoCue and Celera. Focus Diagnostics is a provider of infectious disease testing. Focus Diagnostics develops, manufactures and markets diagnostic products, such as HerpeSelect ELISA tests that detect patient antibodies to specific types of herpes simplex virus, which can be performed on a variety of instrument platforms. Focus Diagnostics sells its diagnostic products to academic medical centers, hospitals and commercial laboratories globally. Focus Diagnostics has an agreement with 3M Corporation for global human diagnostic rights to a compact integrated bench-top instrument for use with real time polymerase chain reaction (PCR) assays. These tests are sold under the Simplexa brand name. In 2011, Focus Diagnostic! s receive! d the CE mark to offer Simplexa tests in Europe, including tests for Cytomegalovirus, Epstein Barr virus, BK virus and clostridium difficile. Focus Diagnostics offers molecular transplant-testing menus in Europe.
HemoCue manufactures and distributes point-of-care testing products globally. HemoCue is a global provider in point-of-care testing for hemoglobin, with a growing market share for glucose, microalbumin and white blood cell testing. HemoCue offers its White Blood Cell Differential System in Europe. Celera offers complexity molecular diagnostic products in segments, such as HIV-1 drug resistance testing, reproductive genetics, transplantation and cardiovascular genetics. It also manufactures and offers the InSure fecal immunochemical test (FIT) for screening for colorectal cancer.
The Company competes with Laboratory Corporation of America Holdings, Inc.
Advisors' Opinion:- [By Rich Duprey]
Diagnostic information specialist Quest Diagnostics (NYSE: DGX ) will acquire the lab-related�clinical outreach service operations of California-based hospital system Dignity Health, serving doctors and patients in parts of California and Nevada.�
- [By James E. Brumley]
And make no mistake - the market wants what CLRX is offering. MedPage Today, a property of Everyday Health, Inc. (NASDAQ:EVDY), Affymetrix Inc. (NASDAQ:AFFX), and Quest Diagnostics Inc. (NYSE:DGX) are just some of the companies that have become paying subscribers to the CollabRx service. If that many reputable names are on board, clearly the service is the real deal.
- [By John Udovich]
On Tuesday, small cap cancer diagnostic stock Myriad Genetics, Inc (NASDAQ: MYGN) jumped 11.42% in one day, meaning its worth taking a closer look at the stock along with the performance of small cap cancer diagnostic stocks like Rosetta Genomics Ltd (NASDAQ: ROSG) and�Genomic Health, Inc (NASDAQ: GHDX) plus mid cap diagnostic stock Quest Diagnostics Inc (NYSE: DGX). I should mention that we have had�Myriad Genetics in our SmallCap Network Elite Opportunity (SCN EO) portfolio since February 5th and we are already up 18.50%���a nice return in just two weeks time.
Top Mid Cap Stocks To Watch For 2014: Cameco Corporation(CCJ)
Cameco Corporation operates as a uranium producer, supplier of conversion services, and fuel manufacturer. The company?s Uranium segment is involved in the exploration for, mining, milling, purchase, and sale of uranium concentrate. Its operating uranium properties include the McArthur River and Key Lake, and Rabbit Lake located in Saskatchewan, Canada; the Crow Butte located in Nebraska and the Smith Ranch-Highland located in Wyoming; and the Inkai uranium deposit located in Kazakhstan. Cameco Corporation?s Fuel Services segment engages in the refining, conversion, and fabrication of uranium concentrate; and the purchase and sale of conversion services. Its products include uranium trioxide, uranium hexafluoride, and uranium dioxide. This segment also manufactures fuel bundles, reactor components, and monitoring equipment to Candu reactors; and provides nuclear fuel and consulting services to Candu operators. The company?s Electricity segment engages in the generation and sale of nuclear electricity, through its 31.6% interest in Bruce Power L.P. This segment operates four nuclear reactors at the Bruce B generating station in southern Ontario, Canada. The company was founded in 1987 and is headquartered in Saskatoon, Canada.
Advisors' Opinion:- [By Dividend]
Cameco (CCJ) has a market capitalization of $7.64 billion. The company employs 3,470 people, generates revenue of $2.234 billion and has a net income of $254.68 million. Cameco�� earnings before interest, taxes, depreciation and amortization (EBITDA) amounts to $704.68 million. The EBITDA margin is 31.54 percent (the operating margin is 11.60 percent and the net profit margin 11.40 percent).
Top Mid Cap Stocks To Watch For 2014: Vornado Realty Trust(VNO)
Vornado Realty Trust is a privately owned real estate investment trust. The trust engages in investment, ownership, and management of commercial real estate. It invests in the real estate markets of United States. The trust primarily invests in office, industrial and retail properties. Vornado Realty Trust is based in New York, New York.
Advisors' Opinion:- [By Ben Levisohn]
In our view, the agreement signals that Pershing Square is willing to sell its stake in the company (17.7% direct ownership/25% total ownership), although it will be done in an orderly fashion and over a period of time. We believe that this could serve as an overhang on the stock as investors wonder if Pershing Square will exit its stake. In addition, [Vornado Realty Trust (VNO)] has stated that it is looking to liquidate its position in JCP.
- [By Robert Hsu]
Vornado Realty Trust (NYSE: VNO) is a traditional REIT.
Unlike mortgage REITs, Vornado actually invests directly in prime real estate properties such as office buildings, and the rents from these properties are what Vornado uses to generate income for unitholders.
- [By Alyssa Oursler]
No wonder�Ackman�and�Vornado Realty Trust�(VNO) have both swallowed their losses in JCPenney stock and headed for the exit.
Sell or Avoid JCPenney StockDespite the losses Ackman and VNO endured, selling JCP when they did ended up being the right move.
- [By Dividend King]
Earnings per share (TTM) came in at $3.48, compared to -$0.33, $1.46, and $4.17 for competitors General Growth Properties Inc. (GGP), Macerich Co. (MAC) and Vornado Realty Trust (VNO), respectively.
Top Mid Cap Stocks To Watch For 2014: Apollo Residential Mortgage Inc (AMTG)
Apollo Residential Mortgage, Inc. is a holding company, which conducts its business primarily through ARM Operating, LLC and its other operating subsidiaries. The Company is a residential real estate finance company that invests in residential mortgage assets in the United States. The Company invests in residential mortgage-backed securities (RMBS) that are issued or guaranteed as to principal and/or interest by a federally chartered corporation, such as Fannie Mae (Freddie Mac), or an agency of us the United Sates Government, such as Ginnie Mae (collectively, the Agencies, with RMBS being issued or guaranteed by the Agencies being referred to as Agency RMBS), whose underlying collateral includes fixed rate mortgages, adjustable rate mortgages (ARMs) and interest-only and inverse interest-only securities (collectively, Agency Derivatives). The Company also invests in RMBS that are not issued or guaranteed by the United Sates government Agency (non-Agency RMBS) and considers investing in residential mortgage loans and other residential mortgage assets. As of December 31, 2011, the Company held a diversified portfolio. The Company is externally managed and advised by ARM Manager, LLC.
The assets that the Company targets for investment: Agency RMBS, Non-Agency RMBS, residential mortgage loans and other residential mortgage assets. Agency RMBS includes primarily whole pool Agency RMBS, and Agency collateralized mortgage obligations. Non-Agency RMBS includes highly rated, as well as non-investment grade and unrated, tranches backed by Alt-A mortgage loans, subprime mortgage loans and prime mortgage loans. Residential mortgage loans includes prime mortgage loans, jumbo mortgage loans, Alt-A mortgage loans and subprime mortgage loans. Other residential mortgage assets consist of interest-only and principal-only Agency RMBS and non-Agency RMBS, inverse floating rate and floating rate securities, and other Agency and non-Agency RMBS derivative securities, as well as other financial assets, includi! ng common stock, preferred stock and debt of other real estate-related entities.
Advisors' Opinion:- [By Tim Melvin]
I sat down this morning and spent some time looking for cheap stocks that might do well regardless of market action in 2014. While bargains are scarce there are still a few to be found. One such bargain is mortgage REIT Apollo Residential Mortgage (AMTG). The stock is trading at less than 80% of quarter-end book value, and management also announced a $50 million share buyback at the same time. There may be some erosion of book value as they look to adopt more credit-sensitive portfolio policies, but I doubt it will be substantial.
- [By Rich Duprey]
Residential mortgage-backed securities REIT�Apollo Residential Mortgage (NYSE: AMTG ) announced yesterday its second-quarter dividend of $0.70 per share, the same rate it's paid for the past three quarters after lowering the payout almost 18% from $0.85 per share.
No comments:
Post a Comment